Eli Lilly And Stock Profit Margin

LLY Stock  USD 778.18  3.28  0.42%   
Eli Lilly And fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
At this time, Eli Lilly's Pretax Profit Margin is fairly stable compared to the past year. Net Profit Margin is likely to rise to 0.19 in 2024, whereas Operating Profit Margin is likely to drop 0.28 in 2024.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Eli Profit Margin Analysis

Eli Lilly's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
 2021 2022 2023 2024 (projected)
Short and Long Term Debt Total16.9B16.2B25.2B26.5B
Total Assets48.8B49.5B64.0B67.2B

Profit Margin

 = 

Net Income

Revenue

X

100

More About Profit Margin | All Equity Analysis

Current Eli Lilly Profit Margin

    
  0.15 %  
Most of Eli Lilly's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eli Lilly And is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Eli Profit Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Eli Lilly is extremely important. It helps to project a fair market value of Eli Stock properly, considering its historical fundamentals such as Profit Margin. Since Eli Lilly's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eli Lilly's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eli Lilly's interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
Competition

Eli Pretax Profit Margin

Pretax Profit Margin

0.19

At this time, Eli Lilly's Pretax Profit Margin is fairly stable compared to the past year.
Based on the latest financial disclosure, Eli Lilly And has a Profit Margin of 0.1536%. This is 101.37% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The profit margin for all United States stocks is 112.09% lower than that of the firm.

Eli Profit Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eli Lilly's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eli Lilly could also be used in its relative valuation, which is a method of valuing Eli Lilly by comparing valuation metrics of similar companies.
Eli Lilly is currently under evaluation in profit margin category among related companies.

Eli Lilly ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

Eli Fundamentals

About Eli Lilly Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly And's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly And based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2024
Pretax Profit Margin 0.19  0.25 
Operating Profit Margin 0.30  0.28 
Net Profit Margin 0.15  0.19 
Gross Profit Margin 0.81  0.62 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Eli Lilly And offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eli Lilly's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eli Lilly And Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eli Lilly And Stock:

Complementary Tools for Eli Stock analysis

When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
CEOs Directory
Screen CEOs from public companies around the world
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.13
Dividend Share
4.52
Earnings Share
5.81
Revenue Per Share
37.908
Quarterly Revenue Growth
0.281
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.